TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07297875: A Phase Ⅰ/Ⅱ, Open-Label Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

Sponsor: Abbisko Therapeutics Co, Ltd · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 110 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,769,180

Rescue Site Savings

+$3,160,640

Unlock Full NCT07297875 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07297875 Rescue Dossier →